IP Library › Granted Patent US 7,150,881
Granted Patent B2
US 7,150,881 · App. 08/883,075 · Granted Dec 19, 2006

Adhesive mixture for transdermal delivery of highly plasticizing drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,150,881
App. No.
08/883,075
Granted
Dec 19, 2006
Kind
B2
Abstract

Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.

Claims (18)

1. A transdermal delivery system which has been dried at a predetermined processing temperature consisting essentially of a blend of:

(a) one or more hydrophobic acrylic polymers; and

(b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperatures,

wherein said system is substantially free of both water and liquids other than said at least one drug having a boiling point (i) below said predetermined processing temperature and (ii) equal to or greater than the boiling points of the low molecular weight drugs.

2. The transdermal delivery system of claim 1 wherein said acrylic polymers include a C 4 –C 12 alkyl acrylate.

3. The transdermal delivery system of claim 2 wherein said acrylic polymers include a C 1 –C 4 alkyl acrylate hardening monomer.

4. The transdermal delivery system of claim 3 wherein said acrylic polymers include a functionalizing monomer.

5. The transdermal delivery system of claim 4 wherein said acrylic polymers include a cross-linking agent.

6. The transdermal delivery system of claim 1 wherein said at least one of said one or more drugs has a molecular weight of less than about 300 MW.

7. The transdermal delivery system of claim 1 including from about 3% to 35% of said therapeutically effective amount of one or more drugs.

8. A transdermal delivery system which has been dried at a predetermined processing temperature consisting essentially of a blend of:

(a) a hydrophobic acrylic polymer; and

(b) a therapeutically effective amount of a drug having a low molecular weight and being a liquid at or about room temperature, wherein said system is substantially free of both water and liquids other than said drug having a boiling point

(i) below processing temperature and

(ii) equal to or greater than the boiling points of the low molecular weight drug,

whereby said transdermal drug delivery system, subsequent to processing, is free of said water and liquids other than said drug.

9. The transdermal delivery system of claim 1 wherein said at least one of said one or more drugs comprises selegiline.

10. The transdermal delivery system of claim 8 wherein said drug comprises selegiline.

Assignments (3)
PATENT RELEASE Recorded Dec 10, 2012
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: DEY PHARMA L.P. (F/K/A DEY, L.P.); MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; SOMERSET PHARMACEUTICALS, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC.
Reel/Frame 029440/0967 →
SECURITY AGREEMENT Recorded Nov 21, 2011
From: MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); SOMERSET PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.)
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 027270/0799 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2011
From: JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: MYLAN TECHNOLOGIES, INC.; DEY, INC. (F/K/A DEY LABORATORIES, INC.); MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.); MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC. (F/K/A MYLAN LABORATORIES INC.)
Reel/Frame 027261/0928 →